Vasoplegic Syndrome after Oral Nimodipine Application in Patients with Subarachnoid Hemorrhage

URN to cite this document:: urn:nbn:de:bvb:355-epub-314220
DOI to cite this document:: 10.5283/epub.31422

Bele, Sylvia ; Scheitzach, J. ; Kieninger, Martn ; Hochreiter, A. ; Schödel, Petra ; Bründl, Elisabeth ; Schebesch, Karl-Michael ; Brawanski, Alexander

Preview

PDF
(1MB)

Date of publication of this fulltext: 05 Mar 2015 12:48

Alternative links to fulltext:DOI Publisher

Details

Preview

Export bibliographical data

Abstract

the underlying aneurysm leading to decrease of immediate complications such as rebleeding, cerebral vasospasm remains the major cause for mortality and morbidity after subarachnoid hemorrhage. The only FDA approved drug for treatment of cerebral vasospasm is the calcium antagonist Nimodipine that has shown beneficial effects on outcome. It is safe, cost efficient and the most widely studied drug ...